#1Syngene Putting Science to Work Investor Presentation January 2024#2Safe harbour " Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts, our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition. Syngene 77 Putting Science to Work 2#3Contents 1 Operating Highlights 2 Syngene - Putting Science to Work 3 Syngene strengths 4 Financials 5 Shareholding and Share Information Syngene Appendix Syngen Synne Syngene Putting Science to Work 3#41 Operating Highlights Syngene#5• Q3 and 9 Months FY24 performance Operating Highlights The third quarter was underpinned by positive performance in Development and Manufacturing Services as well as in the Dedicated Centers. Performance in Discovery Services was impacted by the slowdown in biotech funding In Manufacturing Services, the Company continued to make good progress on the long-term biologics manufacturing partnership with Zoetis. Syngene concluded the acquisition of biologics manufacturing facility from Stelis Biopharma Ltd. Once operational, the acquisition will add 20,000 litres of biologics drug substance manufacturing capacity to Syngene's existing capabilities. It also includes a commercial scale, high speed, fill-finish unit, which is an essential capability for drug product manufacturing. The facility is expected to be operational in the second half of FY25, subject to regulatory approvals. In Discovery Services, the Company added an assay biology capability at the Hyderabad campus to complement the existing Drug Metabolism and Pharmacokinetics (DMPK) and Compound Management facilities Updated guidance: Revenue growth for the full year around double digits on a constant currency basis compared to earlier guidance of mid teens growth Syngene Q3 Financial Highlights Revenue from Operations: 9% YoY Total Revenue: Rs 8,828 Mn Reported EBITDA: Rs 2,608 Mn Profit After Tax*: Rs 1,145 Mn EBITDA from operations margin 27% Profit after Tax* margin 13% PAT✶ 4% YOY 9 Months FY24 Financial Highlights Revenue from Operations: 17% YoY *before exceptional items Total Revenue: Rs 26,462 Mn Reported EBITDA: Rs 7,720 Mn Profit After Tax*: Rs 3,299 Mn EBITDA from operations margin 27% PAT* 16% YoY Putting Science to Work 5#62 Syngene - Putting Science to Work Syngene Synge Close the when nat#7Partner in innovation: #Putting science to work Who we are and what we do We aim to be a world class partner delivering innovative scientific solutions for clients We offer integrated solutions across research, development and manufacturing Sector expertise include pharmaceuticals, biotech, nutrition, animal health, consumer goods and specialty chemicals Our team includes more than 6,000 scientists out of total 8,500+ headcount, operating across 3 state-of- the-art campuses located in India's leading life science hubs: Bangalore, Mangalore and Hyderabad Established track record in discovery research and development for small and large molecules. Emerging presence in commercial manufacturing Syngene Putting Science to Work 7#8Our journey so far Foundation . Operations started Expansion of R&D Lab Granted 100% EOU status by the Government of India 1993- 2000 Syngene Globalization and strategic collaboration • Expanded into formulations development • Contract with Endo Pharmaceuticals to develop novel anti cancer biological therapeutic molecules • Extension of collaboration with BMS; . Merger of Clinigene • Crossed annual turnover of Rs. 5 Billion 2001- 2009 2010- 2014 Expansion • • Expanded service offerings to include chemical development, safety assessment, biologics development Collaboration with BMS to set up BBRC, Syngene's first dedicated R&D Center 2015- 2018 IPO and further collaborations IPO and listing Collaboration with Amgen to set up a dedicated R&D center 2019 - 2024 Continued investments and growth Expanded collaboration with BMS, Amgen and Zoetis • Expansion of IDD platform • Laboratory capacity expansion in Bangalore and Hyderabad • • • Expansion in Mangalore for commercial API manufacturing Capacity and capability addition in Biologics manufacturing Entered in long-term partnership with Zoetis for Biologics commercial-scale manufacturing Commissioned sterile fill-finish facility in Bangalore Acquired multi-modal biologics manufacturing facility from Stelis Biopharma Ltd Putting Science to Work 8#9Key facts and figures 898 400+ active clients 15 13 out of top pharma companies are clients 400+ patents held with clients World class infrastructure 3 campuses in Bangalore, Hyderabad and Mangalore qualified to meet international standards Rs. 45,589 Mn (US$567Mn*) Gross Block of Investments ^ ..ot ୮୦) Rs. 32,638 Mn (US$406Mn*) FY23 Revenue dl Rs. 4,644 Mn (US$58Mn*) FY23 PAT ~8,500+ headcount including ~6,000+ talented scientists அ 75% energy from renewable sources All figures are as on March 31, 2023, unless otherwise specified. @ca. Rs 80/US$ Syngene ^Tangible and Intangible Assets Syngene Putting Science to Work 9#10Our strategic priorities Research: Discovery Services Provide end-to-end therapeutic discovery capabilities including differentiating research technologies and platforms, across many disciplines, disease areas and therapeutic modalities Research: Dedicated Centers Continue to strengthen our existing partnerships with Amgen, Bristol Myers Squibb (BMS) and Baxter through the dedicated centers which provide: a strong foundation for future planning; revenue visibility over the medium to long term; and predictable cash flows Operational Excellence Focus on customer delivery through operational excellence Syngene Development and Manufacturing Services - Small Molecules Leverage existing capabilities to offer integrated Chemistry, Manufacturing, and Controls (CMC) solutions Secure US FDA and other major global regulatory approvals for the small molecule commercial scale manufacturing facility as a platform to attract a broader scope of projects Development and Manufacturing Services - Large Molecules Drive an integrated approach for biologics development and manufacturing to provide a one-stop- shop capability from drug discovery to commercial manufacturing for biologics Accelerate capacity build-up People Develop strong leaders and managers while offering all employees career- long learning opportunities Environmental, Social and Governance (ESG) Committed to Science-based targets and operate in a responsible and sustainable manner. Putting Science to Work 10#11Our broad capabilities, spanning the value chain, facilitate integration and captures additional benefits for clients Research business Discovery Services he sash door 1 not in use Development and Manufacturing business Dedicated R&D Centers Development Services Manufacturing Services Flexible Platform with capability across multiple modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACS SynVent - our proprietary platform for Integrated Drug Discovery SARchitect- our proprietary platform for data visualization and analysis, including features specifically designed to foster collaboration between scientific experts across geographies Syngene Ring-fenced infrastructure for exclusive operations for an individual client Dedicated, multi-disciplinary team of scientists Access to entire Syngene ecosystem for specialist research and development operations Pre-clinical to clinical trials Drug substance and drug product development Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate CGMP-compliant manufacturing of clinical supplies, and registration batches for small molecules Manufacturing of small and large molecules for commercial supplies CGMP-compliant facilities State-of-the art API manufacturing and Biologics manufacturing facilities Putting Science to Work 11#12Sustained investment in skilled workforce and world class infrastructure: a catalyst for expanded client base and strong revenue growth Constantly expanding skilled workforce Number of scientists 2.4x of *FY16 2500+ 6000+ Growing infrastructure More than doubled infrastructure that is qualified to meet international 0.9 standards 2 Increasing client base Strong revenue growth 60% + increase in client base ~3x revenue from FY16 250+ 400+ 11 32 2 FY16 FY23 FY16 FY23 FY16 FY23 FY16 FY23 Infrastructure (in Million sq. ft.) INR Bn 12 Syngene * Year of IPO Putting Science to Work 12 12#13Strategic investments augment cash flows and EPS, driving consistent shareholder returns 13 Improving EPS Increasing operating cash flow Increasing market capitalization EPS doubled since *FY16 Annual operating cashflow 2.6 x of FY16 3x market capitalization since FY16 5.7 FY16 11.6 3.1 8.2 77 239 FY23 FY16 FY23 FY16 FY23 INR INR Bn INR Bn Syngene * Year of IPO Putting Science to Work 13#143 Syngene strengths Syngene#15Syngene strengths A global scale CRO/CDMO • • • Integrated Drug Discovery, Development and Manufacturing service provider Small and large molecules, ADCs, oligonucleotides Listed on Indian Stock Exchanges (NSE and BSE) Syngene $ Solutions through innovation • IP fully assigned to clients • • Track record of data management and security Over 400+ patent filings by clients recognizing Syngene scientists Science in our DNA • • • Located in 3 top India life science hubs: Bangalore, Mangalore and Hyderabad ~6000+ qualified scientists including ~500 PhDs (~6,000+ total headcount) Resilient supply chain management 2 Mn+ sq. ft. world-class R&D and manufacturing infrastructure 888 Quality matters Fully digitized quality organization • Strong compliance track record with global regulators • • US FDA, EMA and PMDA approved, GLP certified, AAALAC accredited facilities 78 client and regulator audits in the last financial year Blue chip client list + 400+ active clients • • . Partnering with large / mid-size / emerging biopharma and other industries Clients concentrated in US, Europe & Japan Track record of working with diverse industry sectors Making a difference • Partnerships have delivered numerous clinical candidates Delivery history for integrated CMC programs up to clinical trials and beyond Putting Science to Work 15#16Our end-to-end platform enables us to be a 'one-stop-shop' for discovery, development and manufacturing (small molecules and biologics) Small Molecules 16 Syngene Antibody-Drug Conjugates Discovery Development Manufacturing Chemistry Drug Substance Clinical Supplies Biology Biologics Oligonucleotides Drug Product Integrated Drug Substance - Drug Product HPAPI Safety Assessment Specialty Molecules HPU* (Phase 1) Integrated Drug Discovery Bio Analytical Lab (Large Molecules) Stability & Analytical Commercial Supplies Therapeutic Antibody Discovery & Engineering; Cell Line Development Services Bioprocess Development, Process Characterisation, Clinical Manufacturing (Microbial & Mammalian) Computational and Data Sciences: Bioinformatics, integrative analysis, target dossiers, systems modeling, cheminformatics and Al * Human Pharmacology Unit Putting Science to Work 16#17Experienced workforce: building capabilities and careers ~8,500+ total headcount Inspiring technical excellence and providing opportunities to grow 6000+ scientists delivering high quality solutions - create a competitive edge Nurturing young talent and enhancing science skills Syngene Training Academy offers new graduate recruits a six-month extended induction to help them understand the Company's vision and values while acquiring the skills to be an industrial scientist Science Certification Program is open to all employees to enhance their capabilities keep their skills up to date and provide opportunities for continuous learning ■ PhDs ■Master's Degree Others 9% 20% 71% All figures are as on March 31, 2023 Syngene Developing leaders and managers Promoting workplace diversity . . Emerging Leaders Development Program is designed to help strong managers transition from managerial to leadership roles Manager Development Program is designed for first- and second-line managers to develop basic management skills and performance management to help them manage their teams and ensure that they are making a positive contribution to the organizational goals • The Company has strong equal opportunity policies to protect against all forms of discrimination and provide a workplace where all employees can deliver their best work Support provided to parents of young families. 28% of our workforce are female and 20% of senior management positions are held by females Putting Science to Work 17#18Extended our state-of-the-art infrastructure & new capabilities in different locations within India to meet our strategic partners needs... HQ campus at Bangalore, India 90 Acres (3,64,217 sq. mt) where most of Syngene's capabilities are housed today 18559994 Syngene Biologics Discovery development & and 2x manufacturing plants in Bangalore, India 18 Fully functional R&D Centre at Genome Valley, Hyderabad, India API manufacturing Commercial manufacturing to support product launch located at Mangalore, India Putting Science to Work 18#19We currently operate a range of successful collaboration models • • • 滥 Dedicated R&D Labs • Dedicated scientific and support personnel customized and managed to partner requirements Dedicated infrastructure implemented and maintained by Syngene based upon partner specifications Access to additional R&D, Manufacturing and support functions at Syngene Long-term (5-7 years) contractual commitment . • 2 Full time equivalent (FTE) Dedicated scientific resources selected from partner-specified disciplines Deliverables and team composition evolve as project advances Typically 3 year contract term ensures team continuity, adjustable with specified notice period Effective for longer-term research commitments 3 Fee For service (FFS) • 4 Risk-reward pre-agreed milestones • Flexible, on-demand resources with targeted skill sets • Rewards based on clearly defined, • Clearly defined project, limited in scope and deliverables • Project scope spans drug Effective way to managed fluctuating demand, ad-hoc requests or uncertain quantity of work discovery, product development or truly end to end across both and are open to any single or combination of above 19 Syngene Putting Science to Work 19#20Our experience spans multiple industry segments and partners us with global leaders across the world... Bristol Myers Squibb GSK sanofi NOVARTIS AMGEN Merck Boehringer Ingelheim Baxter Albireo AN IPSEN COMPANY AMPHISTA THERAPEUTICS idorsia Genmab ASCENEURON 000 BOGO PharmAust LIMITED saniona C4 Therapeutics Large & Mid-Sized BioPharma Syngene BAUSCH+LOMB Zoetis FMC Givaudan Elanco essilor Merck DOW Dow AgroSciences PURINA Beiersdorf BAYER BAYER KRATON Unilever 0000 + E Emerging BioPharma (EBP) Animal Health AgroChem CPG Chemicals/ Polymers Putting Science to Work 20#21Operational robustness driving strategy execution Continuous improvement embedded in operations driven by certified operational leaders Six Sigma Black Belt certified staff in each service line and support function Green belt certified staff across operations All employees white belt certified Focused execution through strong Project Management Structured program management for executing client projects enabled by SynPro platform and SynPro Academy ensuring delivery of client projects Quality management system: digitized and audit-ready 80 customer and regulator audits in the last financial year 8 successful USFDA audits in the last 4 years Digital as a differentiator Al capability in all research teams IoT for maintenance and infrastructure reliability Data Management, IT infrastructure and security systems to strengthen our proposition as a strategic partner to clients Client-focused commercial organization Leaders based in the US, Europe, UK and Asia Close to client locations Strategic Sourcing that makes a difference Strategic supplier management to avoid supply chain disruption Supply distributed across the world to ensure business continuity Syngene Putting Science to Work 21#22We are harnessing digitization and automation through our Lab 4.0 strategy At Syngene, we have adopted Lab 4.0, deploying technology for compliance, as an optimizer and as an augmenter Online management of specifications, procedures, policies, checklist, manuals, BMR, SMF, TTD, protocol, reports Certification as per ISO 13485:2016, ISO/IEC 27001 and ISO 9001:2015 requirements • Online document storage and issuance Online tracking of files Document Management Systems (DMS) Manage QC workflow, integrates instrument and Laboratory Information Management manage samples and associated information Systems (LabWare LIMS) 22 Syngene Digitize all paperwork related to Quality Management system with no manual Intervention and automated notifications TrackWise Radio Frequency Identification System(RFID) Learning Management Systems (LMS) Online Training Platform which tracks learner progress and performance Putting Science to Work 22#23Committed to safety and sustainability Safety is our first priority • • • • Accredited with ISO 45001:2018 for Occupational Health and Safety (OH&S) measures Risk assessments are an integral part of our operation: a proactive approach in incident prevention Kavach, our flagship safety program, has delivered improvement in safety metrics and drives focus on industrial safety for all employees Lost time injury frequency rate (LTIFR): 0.08 • 69,280 hours of EHSS training Committed to environmental protection • • • Committed to Science-based targets for greenhouse gases 90+% of total hazardous and non-hazardous waste recycled 75% of energy procured from green energy sources 3.8% YoY reduction in energy usage 2683 MT equivalent CO2 savings from energy conservation • 52834 MT equivalent CO2 savings from green power. 40% YoY freshwater savings achieved 71389 KL fresh water saved from recycling, reusing and rainwater harvesting. • 1021 KL water rainwater harvested Refer to the CSR link on our website to know about our corporate social responsibility pursuits on healthcare, education, environment, rural development Refer to the ESG Report on our website to know more Syngene All figures are as on March 31, 2023, unless otherwise specified Putting Science to Work 23#24International accreditations Syngene • USFDA, OHSAS 18001 • GLP, cGMP, AAALAC & CPCSEA Certified facilities • CAP accreditation, ISO/IEC 27001:2013 accreditation . EMA and PMDA approved, AAALAC accredited facility • The safety assessment laboratories and large molecule bioanalytical lab are ISO IEC 17025:2017 certified by the National Accreditation Board for Testing and Calibration Laboratories (NABL) Syngene Putting Science to Work 24#25We have consistently received industry recognition for our scientific capability and business excellence CMO Leadership Award Winner 2020 - under Categories: Capabilities, Compatibility, Expertise and Service Bioprocessing Excellence Awards 2020 in the category 'Bioprocessing Excellence in South Asia- Viral Clearance and Safety Testing' CMO Leadership Awards 2022 Presented by Life Science Leader and Outsourced Pharma • CMO Leadership Award Champion 2022 - Presented by Life Science Leader and Outsourced Pharma Golden Peacock Award for Excellence in Corporate Governance for 2021 by the Institute of Directors at the 'Golden Peacock Awards Ceremony' The 2022 Brandon Hall Group HCM Excellence Bronze Award In Leadership Development for 'Best Unique or Innovative Leadership Program' The 2022 Brandon Hall Group HCM Excellence Bronze Award In Leadership Development for 'Best Advance in Compliance Training' . Great Place to Work Certified™ Company • • (ASSOCHAM) CSR & NGO Awards 2020 for our contribution to COVID-19 relief work in Karnataka. • Asia Pacific Biologics CMO Excellence Awards 2022 - For Quality • Biopharma Honours Award 2022 - For Viral Testing Facility by Informa Markets Most Preferred Workplace 2022 - Award by MarksmenDaily.com Golden Peacock National Quality Award 2023 For meeting the overall requirements of the Golden Peacock Excellence Model Biopharma Excellence Awards 2023 For Best Contract Development and Manufacturing Organization (CDMO) 2019 2020 2021 2022 2023 9M 2024 • • • • • Ranked as one of the 25 fastest growing companies in India by Outlook Business CMO Leadership Awards 2019 - Presented by Life Science Leader Magazine FICCI CSR Award for Environmental Sustainability - At the 17th Edition of the awards in New Delhi Safe Workplace Champion Award - At the 8th Manufacturing Supply Chain Summit and Awards Best Leadership Development Program for Middle Management Award At the 6th Global Training and Development Leadership Awards India Pharma Award 2019 - For "Excellence in Contract Research and Manufacturing Services" at CPhI & P-MEC India Expo. Utthama Suraksha Puraskar 2019 - (Pharma and Chemical Manufacturing Category) by National Safety Council of India (NSCI). Leadership Awards Syngene Dream Companies to Work Award at the 29th Edition of the World HRD Congress Awards. Asian Leadership Award for Excellence in Branding and Marketing in the Contract Research Development and Manufacturing category CRISIL awards Syngene Top score among Indian Pharma - for Environment Safety Governance (ESG) Syngene ranked #69 in Fortune India magazine's list of 'Top 100 Indian wealth creators 2021' India Pharma Awards 2021 for Operational Excellence-Manufacturing organized by Informa Markets, India Best Governed Company in the Listed Segment: Medium Category at the 21st National Awards for Excellence in Corporate Governance by The Institute of Company Secretaries of India (ICSI) Most Innovative New Learning Programme at the L&D Vision & Innovation Award organized by Transformance Forums Mahatma Award 2021 under Health & Wellbeing Category Best Corporate Foundation Award at the World CSR Congress Golden Peacock Award 2023: For risk management practices under the Pharmaceutical sector category. Awarded India Best Managed Company by Deloitte Kaizen Excellence Awards:, Won four gold awards at QCFI under different categories Supply Chain Champion Award, 2023: Winner in the ISCM Supply Chain Ranking in the pharmaceutical sector Best Overall Sustainable Performance (Pharmaceutical) 2023 at the 2nd Edition India Sustainability Conclave & Awards 2023 Excelled at CII National Six Sigma Competition winning 4 Platinum awards. Putting Science to Work 25#26Robust risk management framework • Identify and mitigate risk in respective business areas Risk Owner Syngene Syngene has a risk management framework to identify, monitor, report and manage risk Every risk owner monitors and manages risks relevant to their area of responsibility • Executive Committee (EC) Sign-off on Enterprise Risk Framework annually Review and approve the key updates to enterprise risks and deep-dive into few risk areas every quarter Sign-off on Enterprise Risk Framework annually Ensure that appropriate measures are in place to mitigate the risks Review updates to enterprise risks and deep dive into few risk areas every quarter Risk identification Risk assessment Risk analysis and rating Board Risk Committee Board of Directors(BOD) • Provide strategic direction on mitigation of risks Ensure principal risks are properly managed Risk mitigation Monitoring and reporting Refer Annual report for complete risk profile and risk mitigation strategy Putting Science to Work 26#274 Financials + Syngene 00#28Q3FY24 financial highlights Particulars Q3 FY24 Q3 FY23 YOY change Q2 FY24 QoQ change Revenue from operations 8,535 7,859 9% 9,101 -6% Other income 293 172 70% 216 35% Balance Sheet Highlights Reported revenue 8,828 8,031 10% 9,317 -5% Material costs 2,374 2,061 15% 2,672 -11% As on 31st December 2023 Staff costs 2,405 2,192 10% 2,412 0% Other direct costs 254 264 -4% 275 -8% Shareholders' funds 40,284 Other expenses 1,063 876 21% 1,022 4% Net Fixed assets 37,152 Foreign exchange (gain)/loss, net 124 156 -21% 179 -31% Other net assets (1) -842 EBITDA 2,608 2,482 5% 2,757 -5% Net cash/(debt) (2) 3,974 EBITDA Margin 30% 31% 30% Total Use of Funds Depreciation and Finance Cost 1,189 1,083 10% 1,176 1% 40,284 PBT 1,419 1,399 1% 1,581 -10% Tax 274 302 -9% 361 -24% PAT before exceptional items 1,145 1,097 4% 1,220 -6% PAT Margin 13% 14% 13% PAT after exceptional items* 1,115 1,097 2% 1,167 -4% *(Exceptional item (net of tax) in FY24 pertains to transaction costs relating to the acquisition of multi modal facility (Unit 3) of Stelis Biopharma Limited (SBL) (1)Other Assets calculated as (Inventories + Trade Receivables + Unbilled Revenues + Advance Tax + FX premium less (Trade payables + Others current liabilities) at the end of the year (2) Net cash/(Net debt) calculated as the Cash & cash equivalents (Cash and bank balances + Current investments+ Fixed deposits) less Total debt (Short-term borrowings + Long-term borrowings) at the end of the year Syngene All figures in Rs. Mn unless otherwise specified Putting Science to Work 28#299MFY24 financial highlights Particulars Revenue from operations Other income Reported revenue Material costs 9M FY24 9M FY23 YoY change 25,717 21,985 17% 745 481 55% 26,462 22,466 18% 7,274 5,664 28% Staff costs 7,105 6,347 12% Other direct costs 805 835 -4% Other expenses 3,100 2,561 21% Foreign exchange (gain)/loss, net 458 376 22% EBITDA 7,720 6,682 16% EBITDA Margin 29% 30% Depreciation and Finance Cost 3,491 3,055 14% PBT 4,229 3,627 17% Tax 930 771 21% PAT before exceptional items 3,299 2,856 16% PAT Margin 12% 13% PAT after exceptional items* 3,214 2,856 13% All figures in Rs. Mn unless otherwise specified Syngene *(Exceptional item (net of tax) in FY24 pertains to transaction costs relating to the acquisition of multi modal facility (Unit 3) of Stelis Biopharma Limited (SBL) Putting Science to Work 29#305 Shareholding and Share Information Syngene#31Syngene and Biocon Group Syngene Syngene is an operationally independent publicly listed subsidiary of Biocon Limited, established in 1993 as India's first Contract Research Organization. Company has 25+ years of experience in novel molecule discovery, development and manufacturing services Biocon Biocon Limited, founded in 1978, is an innovation-led global biopharmaceuticals company and has majority holding in key operating entities including Syngene Syngene • Integrated services: Discovery research Development Manufacturing small/large molecules Syngene including operating subsidiaries other than Syngene • Product Based • Biosimilars • Formulations and Compounds Alternative Therapeutic Drugs Biocon * Putting Science to Work 31#32Shareholding and Share Information Syngene *As on 31 Dec 2023 Syngene's Shareholding Pattern* 0.8% 44.5% 54.8% NSE Ticker Syngene's Share Information* SYNGENE BSE Ticker 539268 ■ Promoter & Promoter Group Market Cap (Rs. Mn) 2,81,993 Public % free-float 45% ■ ESOP Trust Free-float market cap (Rs. Mn) 1,26,897 Share Outstanding (Mn) 402 Putting Science to Work 32#33For more details Visit our website www.syngeneintl.com https://twitter.com/Syngeneintl in https://www.linkedin.com/company/syngene-international-limited https://www.facebook.com/syngeneintl/ ▸ https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkblQ IR Contact: Krishnan G/Suruchi Daga +91 9819992927/+91 8800176009 [email protected] [email protected] [email protected] Media Contact: Shotorupa Ghosh +91 8450977080 [email protected] Syngene Putting Science to Work 33#34Syngene Putting Science to Work Thank you © 2023 Syngene International Limited, Bengaluru, India. All Rights Reserved. Syngene believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Syngene acknowledges the proprietary rights of other companies to the trademarks, product names and such other intellectual property rights mentioned in this document. Except as expressly permitted, neither this documentation nor any part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, printing, photocopying, recording or otherwise, without the prior permission of Syngene International Limited and/ or any named intellectual property rights holders under this document. www.syngeneintl.com Stay Connected